- Report
- May 2025
- 180 Pages
Global
From €3115EUR$3,545USD£2,687GBP
€3461EUR$3,939USD£2,986GBP
- Report
- May 2025
- 150 Pages
Global
From €5228EUR$5,950USD£4,510GBP
- Report
- April 2025
- 200 Pages
Global
From €2188EUR$2,490USD£1,887GBP
- Report
- July 2025
- 172 Pages
Global
From €5140EUR$5,850USD£4,434GBP
- Report
- January 2025
- 133 Pages
Global
From €2635EUR$2,999USD£2,273GBP
- Drug Pipelines
- April 2025
- 80 Pages
Global
From €1757EUR$2,000USD£1,516GBP
- Report
- May 2025
- 175 Pages
Global
From €3945EUR$4,490USD£3,403GBP
- Report
- June 2025
- 150 Pages
Global
From €2372EUR$2,699USD£2,046GBP
- Report
- June 2025
- 170 Pages
Global
From €3954EUR$4,500USD£3,411GBP
- Report
- April 2025
- 251 Pages
Global
From €2197EUR$2,500USD£1,895GBP
- Report
- February 2023
- 100 Pages
Global
From €5228EUR$5,950USD£4,510GBP
- Report
- September 2023
- 170 Pages
Global
From €1749EUR$1,990USD£1,508GBP
- Report
- May 2024
- 200 Pages
Global
From €3646EUR$4,150USD£3,145GBP
- Report
- October 2023
- 145 Pages
Global
From €2768EUR$3,150USD£2,387GBP
- Report
- April 2023
- 147 Pages
Global
From €4349EUR$4,949USD£3,751GBP
- Drug Pipelines
- January 2023
- 30 Pages
United States
From €2416EUR$2,750USD£2,084GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2856EUR$3,250USD£2,463GBP
- Report
- January 2022
- 200 Pages
Global
From €6590EUR$7,500USD£5,685GBP
- Report
- January 2022
- 60 Pages
Global
From €3471EUR$3,950USD£2,994GBP
- Report
- February 2024
- 180 Pages
Global
From €3361EUR$3,825USD£2,899GBP
€3954EUR$4,500USD£3,411GBP

The Huntington Disease Drug market is a subset of the Central Nervous System Drugs market. It is composed of drugs used to treat Huntington Disease, a rare, inherited neurological disorder that causes the progressive breakdown of nerve cells in the brain. Symptoms of the disease include involuntary movements, cognitive decline, and psychiatric disturbances. Currently, there is no cure for Huntington Disease, but medications can help manage symptoms and slow the progression of the disease.
The Huntington Disease Drug market is composed of both branded and generic drugs. Branded drugs are typically more expensive than generic drugs, but they may offer more effective symptom management. The market is highly competitive, with many companies vying for market share.
Some companies in the Huntington Disease Drug market include AbbVie, Teva Pharmaceuticals, and Lundbeck. Show Less Read more